Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TxCell, a specialty biopharmaceutical firm developing novel cell therapies for autoimmune and chronic inflammatory diseases, has raised E10.5 million in a second round of financing.
Subscribe to our email newsletter
This second round, led by TxCell’s longstanding investors Auriga Partners, AXA Private Equity, Bioam Gestion, CDC Innovation and Seventure, will allow the company to progress its development programs on Crohn’s disease (Ovasave), rheumatoid arthritis (CellArthrix) and a number of orphan diseases.
In 2007, the AFSSAPS (the French Agency for Health Product Safety) authorized the company to start its first clinical trial of a Tr1 lymphocyte-based therapy in Crohn’s disease. This round of financing confirms the significant potential of TxCell’s innovative approach and will enable the company to determine the clinical efficacy of treatment with autologous Tr1 cells.